J&J Ready To Capitalize On Zyrtec OTC Launch As Allergy Drug Hits Shelves

Johnson & Johnson's consumer product business is positioned to capitalize on the launch of nonprescription Zyrtec (cetirizine HCl) allergy medicine, J&J CEO Bill Weldon said during the firm's year-end analyst meeting Jan. 22